drugset / Trial / NCT05339217
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to explore the clinical and immunological efficacy of Telitacicept and low dose IL-2 on systemic lupus erythematosus.
Timeline
- Start
- 2023-02-07
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |